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Immunodominant epitopeWe previously showed that the EBV glycoprotein BMRF-2 contains a functional integrin-binding Arg-Gly-Asp
(RGD) domain that plays an important role in viral infection and cell-to-cell spread of progeny virions in oral
epithelial cells. In this study, we found that EBV-seropositive human sera contain antibodies against BMRF-2.
The inhibitory effect of EBV-positive sera on EBV infection of oral epithelial cells was substantially reduced by
pre-incubation of serum samples with the BMRF-2 RGD peptide, suggesting that anti-BMRF-2 human
antibodies possess neutralizing activity. EBV-speciﬁc sera reacted strongly with the BMRF-2 extracellular
domain (170–213 aa) containing the RGD motif, whereas they reacted only weakly or not at all with a
mutated form of the BMRF-2 extracellular domain containing AAA instead of RGD. These data indicate that
RGD motif of BMRF-2 is part of an immunodominant antigenic determinant within the extracellular domain
of BMRF-2 that may contribute to EBV neutralization during EBV reactivation.
© 2009 Elsevier Inc. All rights reserved.IntroductionEpstein–Barr virus (EBV), a member of the herpes virus family and
one of the most common human viruses, is associated with cancers of
both lymphoid and epithelial origin. EBV-related diseases include
Burkitt's lymphoma, Hodgkin's disease, some adult T-cell lymphomas,
infectious mononucleosis, nasopharyngeal carcinoma (NPC), gastric
carcinoma and oral hairy leukoplakia (HL) (Rickinson and Kieff,
2007). More than 90% of the adult human population are infected
with EBV and are carriers of the virus, which exists in a latent state
under normal immune surveillance (Rickinson and Kieff, 2007).
In addition to cytotoxic CD8+ cells, which are the major players in
immune surveillance against EBV (Chapman et al., 2001; de Jong et al.,
2000; McAulay et al., 2009; Rickinson and Moss, 1997; Savoldo et al.,
2001; Savoldo et al., 2007), EBV-speciﬁc antibodies also play a role in
controlling EBV infection (Beisel et al., 1985; Epstein and Morgan,
1983; Finerty et al., 1994, 1992). The most abundant antibodies
against EBV proteins target the viral capsid antigens (VCA) (Pearson
et al., 1983; Ringborg et al., 1983), the early antigen diffuse (EA-D),
and the early antigen restricted (EA-R) (Henle et al., 1971), which are
expressed during the viral lytic cycle (Chapman et al., 2001). Antibody
responses to VCAs and early antigens serve as important criteria for
the diagnosis of EBV infection and understanding of its pathogenesis
(Khanna et al., 1995). It has also been shown that antibodies directed
against the EBV glycoproteins gp350/220 and gp85 have neutralizing
activity, suggesting a role for these in the clearance of reactivated EBVan Francisco, Department of
. Fax: +1 415 476 9364.
ov).
l rights reserved.(Khanna, Burrows, and Moss, 1995; Sashihara et al., 2009; Thorley-
Lawson and Geilinger, 1980). EBVgp350 has been considered a
candidate for a prophylactic EBV vaccine (Morgan, 1992), and
immunization of seronegative children with recombinant gp350 has
been shown to result in the development of neutralizing antibodies
(Gu et al., 1995). Recently reported clinical trials have also shown that
the EBV gp350 vaccine was immunogenic and safe, suggesting that it
may be used for the prevention of EBV in seronegative individuals
(Moutschen et al., 2007; Sokal et al., 2007). Antibody responses may
also develop against EBV latent proteins, including Epstein–Barr
nuclear antigen 1 (EBNA1) and EBNA2 (Rowe et al., 1988); however,
these do not have signiﬁcant neutralizing activity (Moss et al., 1992).
EBV BMRF-2 is a multi-span trans-membrane protein and is
incorporated into the viral envelope (Johannsen et al., 2004; Tugizov
et al., 2003; Xiao et al., 2007). Its extracellular domain contains an
RGD motif, which interacts with β1- and αv-family integrins of oral
epithelial cells, thereby facilitating EBV entry and spread via
basolateral membranes of polarized oral epithelial cells, where
integrins are expressed (Xiao et al., 2008, 2009, 2007). The BMRF-2
open reading frame (ORF) is conserved throughout the gamma herpes
virus family (Coulter and Reid, 2002; May et al., 2005a, 2005b). EBV
BMRF-2 forms a protein complex with the viral protein BDLF-2 and
facilitates the translocation of BDLF-2 to the cell surface (Gore and
Hutt-Fletcher, 2008; Loesing et al., 2009). BMRF-2 and BDLF-2 are
highly expressed in a benign lesion of the oral epithelium known as
hairy leukoplakia (HL) (Hayes et al., 1999; Palefsky et al., 1997;
Peñaranda et al., 1997; Xiao et al., 2007), which occurs primarily in
persons with HIV-associated immunodeﬁciency (Greenspan and
Greenspan, 1997; Greenspan et al., 1987, 1985). The presence of
BMRF-2/BDLF-2 on cell membranes induces the formation of
Table 1
Detection of human anti-EBV antibodies by ELISA.
Sample name VCA p18 IgG VCA p125 IgM VCA p18 IgA EA-D IgG EBNA-1 IgG
Sera
AS-1 +++ − − − +++
AS-2 +++ − − + +++
AS-3 ++ − − − −
AS-4 ++ − − − +++
AS-5 + − − + +++
AS-6 + − + + +++
NPC-1 ++ − + + ++
NPC-2 ++ − + − ++
NPC-4 +++ − − + +++
NPC-5 +++ − + + +++
HL-1 +++ − + − ++
HL-2 +++ − +/− − ++
HL-3 +++ − − − +++
HL-4 +++ − − − ++
HL-5 ++ − + + +++
VCA, viral capsid antigen; EA-D, early antigen diffuse; EBNA, EBV nuclear antigens; AS,
asymptomatic individuals; HL, hairy leukoplakia; NPC, nasopharyngeal carcinoma. “−”,
negative; “+/−”, negative or weakly positive; “+”, moderately positive; “++”,
positive; “+++”, strongly positive.
152 J. Xiao et al. / Virology 393 (2009) 151–159membrane protrusions and cellular processes that may facilitate cell-
to-cell spread of virus (Gill et al., 2008; Loesing et al., 2009).
It has been shown that the RGD motifs of integrin-binding
proteins in parechoviruses, coxsackievirus A9, foot-and-mouth dis-
ease virus and enteroviruses may generate immunodominant
epitopes that substantially increase the immunogenicity of viral
proteins (Joki-Korpela et al., 2000; Liebermann et al., 1991; Mason et
al., 1994). Furthermore, the immunogenicity of peptide antigens
containing the RGD motifs were found to be ten times stronger than
that of peptides without RGD motifs (Shimakage et al., 2003),
indicating that RGD motifs may be components of immunodominant
epitopes. Previously we showed that human sera from EBV-
seropositive individuals signiﬁcantly reduce BMRF-2 RGD-mediated
EBV infection via the basolateral membranes of polarized epithelial
cells (Tugizov et al., 2003), suggesting that the BMRF-2 RGD domain
serves as an immunodominant antigenic determinant for the humoral
immune response and that antibodies to this domain may have
neutralizing activity against EBV. Therefore, our goal in the current
study was to determine whether EBV-seropositive humans have
neutralizing antibodies against BMRF-2 and to examine the role of the
BMRF-2 RGD motif in an anti-BMRF-2 immune response. We
expressed BMRF-2 in B-lymphoblastoid and epithelial cells and
measured the speciﬁc interaction of serum samples with BMRF-2
from three groups of EBV-seropositive people: HIV-negative EBV-
asymptomatic individuals, HIV-negative NPC patients and HIV-
positive individuals with HL. We found that all EBV-seropositiveFig. 1. Expression of BMRF-2 in Akata/BMRF-2 and 293T/BMRF-2 cells. (A) Cells transfecte
visualized in cells using confocal microscopy. Cell nuclei were counterstained in blue. (B) M
total membrane proteins was separated in urea gels. BMRF-2 was detected by Western bloindividuals have antibodies against BMRF-2 and that the immuno-
dominant antigenic epitope (s) is located within the RGD-containing
extracellular domain of BMRF-2.
Results
Collection and characterization of human sera
We collected 15 serum samples from the following: 6 samples
from HIV-negative, healthy individuals without any clinical symp-
toms of EBV-associated disease (asymptomatic serum samples, AS); 4
samples from HIV-negative patients with NPC (NPC samples); and 5
samples fromHIV-infected patients with oral HL lesions (HL samples).
To detect EBV-speciﬁc antibodies in human serum samples, we
performed enzyme-linked immunosorbent assay (ELISA) using three
different EBV proteins as test antigens: VCAs (p125 and p18), EA-D
and EBNA-1. All serum samples were examined for the presence of the
following antibody isotype and antigen speciﬁcity combinations: IgG
anti-VCA, IgM anti-VCA, IgA anti-VCA, IgG anti-EA-D and IgG anti-
EBNA-1. As shown in Table 1, all serum samples were positive for both
VCA p18 and EBNA-1, whereas none of the samples tested positive for
IgM anti-VCA p125 antibodies. IgA anti-VCA p18 antibodies were
found in only one of the six (17%) serum samples from asymptomatic
individuals, three of the four (75%) NPC serum samples, and two of the
ﬁve (40%) HL serum samples. IgG anti-VCA p18 antibodies were found
in all of the serum samples, and IgG anti-EBNA-1 antibodies were
present in all but two samples (Table 1). IgG anti-E-AD antibodies
were detected in three of the NPC samples, one of the HL samples, and
three of the samples from asymptomatic individuals. Thus, all serum
samples were found to contain antibodies against EBV proteins, and
the absence of IgM indicated that none of the donors was infected
recently. However, detection of IgA anti-VCA p18 and IgG anti-E-AD in
NPC and HL patients suggests the possible reactivation of virus in
these donors.
EBV-positive human sera recognize BMRF-2 in both B-lymphocytes and
epithelial cells
Since EBV has a tropism for both B-lymphocytes and epithelial
cells in vivo, we expressed the GFP-tagged BMRF-2 protein in both
Akata 4E-3 B-lymphoblastoid cells and 293T kidney epithelial cells,
hereafter referred to as Akata/BMRF-2 and 293T/BMRF-2, respec-
tively. Expression of BMRF-2 was conﬁrmed by detection of GFP
ﬂuorescence (Fig. 1A), as well as by Western blotting using rat anti-
BMRF-2 serum (Fig. 1B). The BMRF-2 protein was detected in
approximately 95% of Akata/BMRF-2 and 80% of 293T/BMRF-2 cells.
To determine whether EBV-seropositive humans have antibodies
against BMRF-2, we performed immunoﬂuorescence assays with alld with the BMRF-2-GFP fusion gene were ﬁxed, and the GFP ﬂuorescence signal was
embrane fractions of Akata/BMRF-2 and 293T/BMRF-2 cells were isolated and 10 μg of
t assay using rat anti-BMRF-2 antiserum.
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NPC and HL using Akata/BMRF-2 and 293T/BMRF-2 cell lines. BMRF-
2-speciﬁc immunostaining was conﬁrmed by colocalization of anti-
body signal with BMRF-2 GFP signals (Fig. 2). All serum samples
recognized BMRF-2 in both B-lymphoblastoid and epithelial cells
(data not shown), consistent with the ELISA data (Table 1). Fig. 2
shows immunostaining of BMRF-2 in Akata/BMRF-2 and 293T/BMRF-
2 cell lines with the EBV-positive NPC-4 and EBV-negative serum
samples. Cells immunostained with NPC-4 serum were strongly
positive, whereas cells stained with negative serum did not have
speciﬁc signals. All 15 EBV-positive serum samples were highly
reactive to BMRF-2, i.e., 70–100% of BMRF-2 expressing cells of Akata/
BMRF-2 and 293T/BMRF-2 cell lines were BMRF-2-positive. However,
the intensity of BMRF-2 immunostaining levels in both Akata/BMRF-2
and 293T/BMRF-2 cell lines was variable among serum samples.
Analysis of immunostained cells using secondary antibodies againstFig. 2. Detection of BMRF-2 in Akata/BMRF-2 and 293T/BMRF-2 cells using human serum sa
positive NPC-4 (A and B, upper panels) and EBV-negative human sera (Wampole Laboratorie
yellow in merged panels indicates colocalization of the BMRF-2 GFP signal with human serhuman IgG, IgM and IgA showed that BMRF-2 was detected only with
anti-human IgG antibodies, indicating that human antibodies against
BMRF-2 is belong to the IgG class.
Next, to determine whether human anti-BMRF-2 antibodies react
to the protein on the Akata/BMRF-2 and 293T/BMRF-2 cell surfaces,
we performed ﬂow cytometry assays on live cells using all of the
serum samples from the asymptomatic, NPC and HL groups. The results
from these assays are consistent with the ﬁndings from the ELISA and
immunostaining experiments: BMRF-2 was detected on the surfaces of
bothAkata/BMRF-2 and293T/BMRF-2 cells usingall serumsamples. The
mean intensity (MN) of the BMRF-2-speciﬁc ﬂuorescence signal with
the positive serum samples in both cell lines was high and varied
between 55 and 125 (data not shown). Fig. 3 shows the results of
ﬂow cytometry detection of BMRF-2 on cell surfaces of both cell lines
by representative EBV-positive serum samples from asymptomatic,
NPC and HL individuals.mples. Akata/BMRF-2 (A) and 293T/BMRF-2 (B) cells were immunostained with EBV-
s) (A and B, lower panels). BMRF-2 is shown in green, human serum signals are red, and
a-speciﬁc red signal. Cell nuclei were stained in blue.
Fig. 3.Detection of cell surface BMRF-2 by ﬂow cytometry using human serum samples. Akata/BMRF-2 and 293T/BMRF-2 cells were incubatedwith human sera and RPE-labeled goat
anti-human IgG was used to detect binding of human anti-BMRF-2 antibodies to the cell surface. Gray-ﬁlled curves represent EBV-negative human serum (Wampole Laboratories)
and unﬁlled curves indicate EBV-positive serum samples. MN, mean ﬂuorescence intensity.
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that all EBV-positive human sera contain antibodies to BMRF-2 and
that these antibodies recognize both intracellular and cell surface
BMRF-2 in both B-lymphoblastoid and epithelial cells.
The RGD motif serves as an immunodominant epitope for BMRF-2
It has been shown that the RGD motifs of viral proteins are an
essential part of immunodominant epitopes (Joki-Korpela et al., 2000;
Liebermann et al., 1991; Mason et al., 1994). Analysis of the
hydrophobicity plot of BMRF-2 according to the Kyte–Doolittle scale
shows that BMRF-2 is a highly hydrophobic multi-span trans-
membrane protein, except for its RGD-containing extracellular
domain (amino acids 171 to 218), suggesting that this domain
might contain immunodominant epitopes. Therefore, we examined
whether the RGD-containing domain can serve as an immunodomi-
nant region for the induction of the humoral immune response during
lytic EBV infection. The BMRF-2 open reading frame encoding amino
acids171 to 218 was subcloned into a pGEX vector and expressed as a
3 glutathione-S-transferase (GST) fusion protein. A control GST fusion
protein in which RGD was replaced with alanines, was also prepared.
We then examined the reactivity of four different human serum
samples from asymptomatic, NPC and HL donors against the two GST
fusion proteins using a Western blot assay. As shown in Fig. 4, all fourFig. 4.Western blot analysis of human sera reactivity to the BMRF-2 RGD and mutant BMRF-
form, BMRF-2-AAA, were electrophoresed in Tris-glycine SDS-PAGE gels. Reactivity of hu
examined by Western blot assay. As a negative control EBV-negative human serum was usEBV-positive human sera strongly recognized the BMRF-2-RGD
peptide. However, three serum samples, AS-1, HL-1 and HL-2, only
weakly recognized the mutant BMRF-2 AAA peptide, while the fourth
(NPC-1) showed no detectable reactivity with the mutant peptide.
This ﬁnding indicates that the BMRF-2 RGD motif plays an important
role in the antibody recognition capacity to the extracellular domain
(aa 171 to 218).
EBV-positive human sera may contain neutralizing antibodies against
BMRF-2
The above data indicate that the BMRF-2 RGD domain might serve
as an important antigenic determinant for the stimulation of the anti-
EBV humoral immune response. Short synthetic peptides have been
used successfully to test the neutralizing effect of antibodies directed
against viral proteins (Hosein et al., 1991; Wang, 1988). Here we
adapted this method to determinewhether anti-BMRF-2 antibodies in
EBV-positive human sera speciﬁcally interact with the BMRF-2 RGD
domain. Six serum samples from asymptomatic, NPC and HL
individuals were pre-incubated with 47 amino acid peptides cleaved
from GST fusion protein containing either the wild-type BMRF-2 RGD
or the mutant BMRF-2 AAA sequence to deplete sera of the RGD-
speciﬁc antibodies. Subsequently, polarized oral epithelial cells were
infected with the EBV B95-8 strain in the presence of the pre-incubate2 AAA peptides. The GST fusion protein containing BMRF-2-RGD peptide or its mutated
man serum samples to these peptides from asymptomatic, NPC and HL groups was
ed (Wampole Laboratories). The GST protein was detected as a loading control.
Fig. 5.Neutralizing activity of EBV-positive human sera pre-treated with BMRF-2 peptides. Human serum samples from asymptomatic, NPC and HL patients were incubated with the
47 aa BMRF-2 RGD or BMRF-2 AAA peptides (A and B) for 1 h and then used for neutralization of EBV B95-8 virus. In parallel experiments (C) the serum samples were incubated with
a shorter (17 aa) BMRF-2 RGD (RRRSIFCARGDHSVASL) or a control, unrelated peptide (GARRNQIYTSGLERRR). Polarized primary tongue epithelial cells were infected with EBV B95-
8 pre-incubated with human serum samples treated with or without peptides. (A) At 3 days post-infection, cells were immunostained using anti-BZLF-1 antibody and examined by
confocal microscopy. Only merged panels are shown; yellow indicates colocalization of BZLF-2 (green) signals with the nuclear marker (red). (B, C) EBV-infected (BZLF-1-positive)
cells were counted, and the percentage of cells infected was determined for each experimental condition. (B) Asterisks indicate statistically signiﬁcant inhibition of EBV-neutralizing
activity using serum samples treated with BMRF-2 peptides as compared with serum samples without peptides (EBV+ sera) (⁎Pb0.05). (C) Asterisks indicate statistically signiﬁcant
inhibition of EBV-neutralizing activity using serum samples treated with a BMRF-2 peptide as compared with serum samples pre-incubated with the BMRF-2 unrelated peptide
(⁎Pb0.05). Error bars show±s.e.m. (n=6). EBV+ sera, pool of 15 samples of EBV-positive sera from asymptomatic, NPC and HL donors. EBV− sera, pool of 2 EBV-negative sera from
commercial sources.
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by immunostaining using monoclonal anti-BZLF-2 (Fig. 5A) anti-
bodies. Incubation of virus with a pool of 15 EBV-positive serum
samples without pre-incubation with BMRF-2 peptides led to
approximately 80% inhibition of infection. Pre-incubation of serum
samples with either the RGD- or AAA-containing peptides both
reduced the neutralizing activity of the serum samples. However, the
degree of inactivation of BMRF-2-speciﬁc antibodies was signiﬁcantly
different between the two peptides (Fig. 5B). Pre-incubation of all six
serum samples with the BMRF-2 RGD peptide led to a signiﬁcant
(approximately 3–5 fold) increase in EBV infection of oral epithelial
cells. In contrast, pre-incubation of these serum samples with the
BMRF-2 AAA peptide had a far more modest effect: four of six serum
samples from asymptomatic and HL donors resulted only moderate
(approximately 2-fold) increases in EBV infection rates, and 2 serum
samples from NPC donors did not increase EBV infection rates at all.
In parallel experiments we examined the neutralizing activity of a
17 amino acid synthetic peptide encompassing the BMRF-2 RGD
domain (aa 192 to 209), as well as that of a BMRF-2 unrelated peptide.
Pre-incubation of the 11 human sera with the RGD-containing peptide
reduced the inhibitory effect of serum samples in EBV infection of oral
epithelial cells by about 2–4 fold (Fig. 5C). Pre-incubation of the serum
samples with the BMRF-2-unrelated control peptide did not affect the
inhibitory activity of human sera against EBV infection. These ﬁndings
indicate that the neutralizing effect of the human sera on EBVinfection of epithelial cells can be abrogated speciﬁcally by the BMRF-
2 RGD-containing extracellular domain, but far less effectively or not
at all by peptides lacking the RGD motif.
Discussion
In this study, we examined the human antibody response to EBV
BMRF-2 in asymptomatic healthy individuals, NPC patients and HIV-
infected patients with HL. All serum samples from the three groups
were positive for EBV and contained IgG anti-VCA p18 and anti-EBNA-
1 antibodies. However, none of the serum samples was positive for
IgM anti-VCA p125 antibodies, indicating that the sera came from
individuals with long-standing EBV infections and not recent, primary
infections (Rickinson and Kieff, 2007). IgA anti-VCA and IgG anti-EA-D
antibodies were found mainly in HL and NPC patients, suggesting
reactivated EBV infection in these individuals (Rickinson and Kieff,
2007). All EBV-positive sera recognized BMRF-2 in B-lymphoblastoid
and epithelial cells, indicating that BMRF-2 is a target of the humoral
immune response. However, recognition of BMRF-2 by all serum
samples, including those from latently-infected (IgG anti-VCA p18-
and IgG EBVA-1-positive samples) and EBV-reactivated individuals
(IgA anti-VCA p18- and IgG EA-D-positive samples) indicates that the
antibody response to BMRF-2 may not serve as a marker for the
reactivation of virus. More likely, antibodies to BMRF-2 appear soon
after primary infection and may serve as markers for seroconversion.
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surface of both lymphocytes and epithelial cells, indicating that the
immunodominant epitopes of BMRF-2 were localized to its extra-
cellular domain. The predicted structure of BMRF-2 suggests that it
might have nine or ten hydrophobic trans-membrane domains and
one major hydrophilic domain (aa 170 to 213 aa) that contains the
integrin-binding RGD motif. We previously showed that this major
hydrophilic domain is exposed at the cell surface and that its RGD
motif is functional for integrin binding (Tugizov et al., 2003). In this
study, we show that mutation of the RGD motif substantially reduces
or eliminates EBV-speciﬁc, human antibody binding to the RGD-
containing extracellular domain of BMRF-2. These ﬁndings indicate
that the RGD motif may serve as a key component of immunogenic
epitopes within the extracellular loop of BMRF-2. Our ﬁndings are
consistentwith published data showing that the RGDmotif is essential
not only for integrin binding, but also for antigenic determination
(Joki-Korpela et al., 2000; Liebermann et al., 1991; Mason et al., 1994).
In human parechoviruses and the foot-and-mouth disease virus, the
RGDmotif of viral capsid protein VP1 has been shown to be critical for
virus attachment, infection and stimulation of the antibody response
(Joki-Korpela et al., 2000; Liebermann et al., 1991; Mason et al., 1994).
It is possible that exposure of the BMRF-2 loop between171 and 218 aa
to the extracellular environment, and the presence of the RGDmotif in
this region, creates a favorable condition for generation of a highly
immunogenic region, i.e., is easily accessible by the humoral immune
system for a strong antibody response.
Experiments with blocking or inactivation of BMRF-2-speciﬁc
antibodies from EBV-positive serum samples with BMRF-2 RGD
peptides (aa 171 to 218) yielded interesting data. These sera failed to
inhibit EBV infection of polarized oral epithelial cells from their
basolateral membranes, indicating that human antibodies against the
BMRF-2 RGD domain may have neutralizing activity against EBV.
Mutation of the RGD motif in the extracellular domain (aa 171 to
218) of BMRF-2 did not completely abolish the ability of this peptide
to inactivate BMRF-2-speciﬁc antibodies in human sera, suggesting
that this extracellular region may contain other immunogenic
epitopes. However, shorter peptides (aa 192–209) also exhibited a
similar degree of inactivation on EBV-positive serum samples,
suggesting that the RGD motif and its ﬂanking amino acid residues
may play an important role in the formation of immunogenic
epitopes. These data are consistent with our previously published
data showing that rat immune serum raised against the BMRF-2 RGD
domain blocks the attachment and entry of EBV in polarized oral
epithelial cells (Tugizov et al., 2003). The immunodominant role of
the BMRF-2 RGD domain in human antibody response is well-
supported by our previous ﬁnding that the generation of highly
reactive rat anti-BMRF-2 immune sera was possible only against
RGD-containing extracellular domain (aa 171 to 218) of BMRF-2
(Tugizov et al., 2003). In contrast, immunization of rats with the N-
terminus (aa 2 to 73) or the C-terminus (aa 315 to 354) peptides of
BMRF-2 did not induce any antibody response or generated low titer
antibodies to BMRF-2, respectively.
Detection of EBV BMRF-2-speciﬁc antibodies in patients with NPC
and HIV-positive individuals with EBV-infected HL lesions suggest
that during ongoing EBV infection these antibodies may not prevent
EBV spread within the oro-nasopharyngeal mucosal epithelium. It has
been shown that naturally occurring neutralizing antibodies against
HSV-1 also do not prevent or reduce the development of epithelial
lesions by reactivated virus (Corey and Spear, 1986), i.e., cell-to-cell
spread of virus within the epithelium.
Cell-to-cell spread of HSV-1 and other alpha herpes viruses occurs
across the lateral junctions of epithelial cells, and a complex of two
viral glycoproteins, gE and gI, plays a key role in this process
(Alconada et al., 1998; Balan et al., 1994; Brack et al., 2000; Dingwell
et al., 1994; Dingwell and Johnson, 1998; Johnson et al., 2001). The gE/
gI complex ﬁrst accumulates in the trans-Golgi network (TGN) and isthen delivered to the cell junction area by basolateral sorting vesicles
(Farnsworth and Johnson, 2006; Johnson et al., 2001; McMillan and
Johnson, 2001). The basolateral sorting of gE/gI leads to the
accumulation of nascent virions at cell junctions and their spread
via neighboring membranes (Farnsworth and Johnson, 2006; Johnson
et al., 2001; McMillan and Johnson, 2001; Polcicova et al., 2005). We
have shown that EBV BMRF-2 also accumulates in the trans-Golgi
network (TGN) and is then transported to the basolateral membranes
of oral epithelial cells and that it plays a critical role in cell-to-cell
spread of virus via the junctional areas of oral epithelial cells (Xiao et
al., 2009). The presence of extensive cell junctions (desmosomes and
both tight and adherens junctions) may prevent penetration of
neutralizing antibodies into these cell-to-cell contact areas and
therefore protect the infectious virions from host immune surveil-
lance (Johnson and Huber, 2002; Sattentau, 2008). Therefore, it is
possible that the presence of anti-BMRF-2 antibodies in EBV-infected
individuals may not have a signiﬁcant effect on the cell-to-cell spread
of EBV within the oral or nasopharyngeal epithelium. However,
human anti-BMRF-2 neutralizing antibodies may contribute to the
control of EBV infection of epithelial cells by cell-free virus. Indeed,
our previous data have shown that BMRF-2-mediated cell-free EBV
infection of oral epithelial cells is reduced by human sera from EBV-
infected individuals and rat immune sera against the BMRF-2 RGD-
containing extracellular domain.
In summary, in this study we provide the ﬁrst evidence that EBV-
infected human sera contains BMRF-2-speciﬁc antibodies, indicating
that the EBV BMRF-2 protein, an important component of virions and
lytic viral infections, may serve as a signiﬁcant target for the humoral
immune response. The immunodominant epitope (s) of BMRF-2 was/
were localized within the BMRF-2 RGD-containing extracellular
domain, between 170 and 213 aa, and seroreactivity to peptides
corresponding to this region may serve as an immunodiagnostic
marker for EBV infection.
Materials and methods
Human serum samples
Serum samples from HIV-negative asymptomatic individuals and
HIV-infected HL patients were provided by the AIDS Specimen Bank
(Department of Oral Biology, University of California, San Francisco,
California). EBV-speciﬁc immune sera fromHIV-negative NPC patients
were provided by E. Lennette (Viralab Inc, Berkeley, California). All
human sera were previously collected from volunteers after providing
informed consent. Use of human sera was approved by the Committee
on Human Research Review Board of the University of California, San
Francisco (UCSF) (CHR approval #RS00908). EBV-negative human
serum was purchased from Blackhawk BioSystem, Inc and Wampole
Laboratories.
Enzyme-linked immunosorbent assay (ELISA)
Commercial ELISA kits were used to determine antibody levels in
human serum samples. ELISA assays were performed to detect anti-
EBV antibodies according to protocols provided by the manufacturers.
The ELISA kits to detect IgG, IgM and IgA antibodies speciﬁc for EBV
viral capsid antigens (VCA p18 for IgG and IgA, and VCA p125 for IgM),
IgG against nuclear antigen-1 (EBNA-1) and IgG against BMRF-1
(early antigen-D (EA-D) were obtained from Wampole Laboratories
(Princeton, New Jersey). The VCA IgA ELISA kit was purchased from
Bio-Quant (San Diego, California). ELISA data were evaluated accord-
ing to protocols provided by the manufacturers as follows: negative
“−”, an OD readings of 0–0.9; negative or weakly positive “+/−”, an
OD readings 0.91–1.0; moderately positive “+”, an OD readings of
1.1–3.0; positive “++”, an OD readings of 3.1–5.0; strongly positive
“+++”, an OD readings of 5.1 and above.
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The EBV-producing marmoset B-lymphoblastoid cell line B95-8
and EBV-negative human B-lymphocytic cell line Akata 4E-3 cells (a
gift from Dr. Hutt-Fletcher at Louisiana State University Health
Sciences Center) were maintained in RPMI 1640 medium supple-
mented with 10% fetal bovine serum and antibiotics. The human
kidney epithelial cell line 293T cells (ATCC, Manassas, VA) were
cultured in Dulbecco's modiﬁed Eagle's medium (DMEM) containing
10% fetal bovine serum (FBS, Hyclone, Logan, UT). Rat anti-BMRF-2
serumwas previously generated in our laboratory by immunizing rats
with a GST fusion protein containing the hydrophilic extracellular
domain of the BMRF-2 protein (aa 178–218). All secondary antibodies
were purchased from Jackson ImmunoResearch Laboratories (West
Grove, Pennsylvania).
Plasmid construction for expression of EBV BMRF-2 proteins and
DNA transfection
The BMRF-2 ORF from EBV B95-8 strain was previously cloned into
a retrovirus vector as described previously (Xiao et al., 2007). The
plasmid expressing the BMRF-2 protein tagged with the green
ﬂuorescent protein and designed for stable expression of BMRF-2
GFP in B-lymphoblastoid cell line Akata-4E-3 cells was transfected
with BMRF-2-GFP using LipofectAmine 2000 (Invitrogen) according
to the manufacturer's the protocol. At 48 h after transfection, cells
were plated into 96-well plates at 104 cells/well in growth medium
containing G418 (500 mg/ml). One half of the culture medium was
replaced with fresh growth medium containing G418 every ﬁve days.
After 3–4 weeks of selection, G418-resistant and BMRF-2-expressing
clones were pooled and expanded. The cell line was designated Akata/
BMRF-2 and was maintained in growth medium containing G418
(400 mg/ml). Transient transfection was used to express BMRF-2 in
293T cells (human kidney epithelial cells) since they are highly
transfectable with more than 80% transfection efﬁciency. Cells were
seeded in 8-well chamber slides or 10 cm Petri-dishes 12–16 h before
transfection so that they would reach 80–90% conﬂuence at the time
of transfection. The BMRF-2 gene was introduced into the cells using
LipofectAmine 2000 (Invitrogen) according to the manufacturer's
protocols. 24–36 h post-transfection, cells were used for experiments.
293T cells transfected with BMRF-2 were designated 293T/BMRF-2.
Flow cytometry analysis
For ﬂow cytometry analysis Akata/BMRF-2 cells were collected
and washed once with ice-cold wash buffer (3% bovine serum album
(BSA) in PBS) by centrifugation (800 rpm for 3 min). 293T/BMRF-2
cells were dissociated with cell dissociation buffer (Invitrogen,
Carlsbad, CA) for 5 min at room temperature and then washed once
with ice-cold wash buffer. The cell pellets were then re-suspended in
wash buffer and each human serum sample (primary antibodies) was
incubated with 106 cells at 1:50 dilution in PBS (pH 7.2) at 4–8 °C with
gentle rocking for 45min. Cells werewashed three timeswith ice-cold
PBS and reactedwith R-Phycoerythrin (RPE)-labeled goat anti-human
IgG as secondary antibodies. Surface expression of BMRF-2 was
measured by FACS in a FACSCAN (Becton-Dickinson, San Jose, CA).
Confocal immunoﬂuorescence microscopy
For immunoﬂuorescence staining, 293T/BMRF-2 cells grown on
chamber slides were washed once with PBS and air-dried. Akata/
BMRF-2 cells were washed once with PBS, re-suspended in PBS (106
cells/ml), and 10 μl of cells was dropped onto a glass slides and air
semi-dried. The cells were then rinsed once with PBS and ﬁxed with
methanol/acetone (50/50) for 30 min at−20 °C. EBV-positive human
sera were then applied to the slides for 45 min and then washed 3times with PBS. Texas-red labeled goat anti-human IgG was used as
secondary antibody incubated at room temperature for 45 min. Cell
nuclei were stained with TO-PRO-3 (blue ﬂuorescence) or propidium
iodide (red ﬂuorescence) for 10 min. Immunostained cells were
analyzed using a krypton-argon laser coupled with a Bio-Rad
MRC2400 confocal head. The data were analyzed using Laser Sharp
software.
Peptide neutralization assay
For the peptide neutralization assay we used the BMRF-2
extracellular domain containing the RGD motif (BMRF-2 RGD, amino
acids 171 to 218), which was previously constructed as a glutathione-
S-transferase (GST)–BMRF-2 RGD fusion protein. The QuikChange
Site-Directed Mutagenesis Kit (Stratagene, San Diego, California) was
used to mutate the RGD sequence in the BMRF-2 RGD peptide using
the GST–BMRF-2 RGD fusion gene as a template and the following
HPLC-puriﬁed primers (Invitrogen). Primers for the BMRF-2 AAA
mutantwere forward primer 5′-cattttctgcgccgccgcagctcattcggtggcatc-
3′ and reverse primer 5′-gatgccaccgaatgagctgcggcggcgcagaaaatg. GST
fusion proteins were propagated in the Escherichia coli Bl-21 strain
(Xiao et al., 2007) and puriﬁed using Sepharose-4 beads. BMRF-2
peptides were cleaved by thrombin (Amersham, Piscataway, New
Jersey) according to protocols provided by the manufacturer. After
thrombin cleavage, peptide fragments were washed three times and
concentrated in PBS using Amicon Ultra-10 centrifugal ﬁlter devices
(Millipore). Endotoxin levels were measured using the Limulus
Amebocyte Lysate assay kit E-TOXATE (Sigma) and were found to be
less than 0.005 EU/mg in puriﬁed protein preps. We also used
synthetic peptides containing the RGD motif of BMRF-2 (RRRSIF-
CARGDHSVASL) and a control, unrelated peptide (GARRNQIYTS-
GLERRR) purchased from Biopeptide Co (San Diego, California).
Peptide neutralization assays were performed according to Wang
et al., (Wang, 1988) with some modiﬁcations. Polarization of oral
epithelial cells and their infectionwith EBVwere described previously
(Tugizov et al., 2003; Xiao et al., 2008). Brieﬂy, primary tongue
epithelial cells were cultured on 24-mm diameter Transwell ﬁlters
(Costar) to form a polarized monolayer. To test the ability of various
RGD domain-related peptides to abrogate the neutralizing activity of
BMRF-2-speciﬁc antibodies in human sera, the sera were ﬁrst diluted
1:50 with PBS and then mixed with BMRF-2 RGD, BMRF-2 AAA, or the
BMRF-2-unrelated control peptide at 100 μg/ml for one h at 37 °C. To
examine the inhibitory effect of the treated sera against EBV infection,
EBV virions of the B95-8 strain were ﬁrst incubated with the peptide-
treated or un-treated human sera at 37 °C for 1 h with gentle shaking.
The above-treated virions were then added to the epithelial cells from
the bottom chamber at 100 virions/cell, and the ﬁlters were incubated
at 37 °C with gentle shaking for 1 h. The medium was then removed
and cells were maintained in growth medium in a 5% CO2 incubator.
Three days after infection, cells were ﬁxed with 3% paraformaldehyde
in PBS at 4 °C for 30 min and immunostained with mouse monoclonal
anti-BZLF-1 antibodies, respectively. EBV protein expression was
visualized by staining the cells with Texas-red labeled goat-anti-
mouse secondary antibodies. EBV-infected (BZLF-1 positive) cells
were analyzed and counted by confocal microscopy.
Western blotting
Membrane protein extraction of Akata/BMRF-2 and 293T/BMRF-2
cells was performed as described previously (Xiao et al., 2007). Brieﬂy,
membrane fractions of BMRF-2 expressing cellswere solubilized in urea
sample buffer (7 M urea, 2 M thioreurea, 1% TX100, 1% DTT, 4% chaps,
and 10 mM Tris, pH 9.5) at room temperature for 1 h. Before loading,
samples weremixed with one-tenth volume of 1 M DTT and denatured
at 70 °C for 10min. Proteinswere then separated on7Murea-SDS-PAGE
gels. The BMRF-2 proteinwas detected using rat anti-BMRF-2 serum. To
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the GST-BMRF-2-RGD and GST-BMRF-2-AAA fusion proteins were
separated in Tris-glycine SDS-PAGE gel, and proteins were detected
using the various human serum samples. The GST protein was detected
using the goat anti-GST antibody (Novus Biologicals).
Statistical analysis
Data were compared using the Student's t test; P values of b0.05
were regarded as signiﬁcant.
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